Kornimate/medical-research-clean huggingface dataset:
sleep, cognition and memory disorder

Conditions: Sleep Architecture; Sleep Disorders; Cognitive Impairment

Summary: the increasing incidence of alzheimer's disease (ad) and related sleep-disorders with the aging of the population is a major issue of public health. the prevalence of sleep disturbances is about 50% in dementia patients. sleep in dementia is mainly characterized by prolonged night-time awakenings, sometimes with longer sleep latency and/or early awakening. the presence of these sleep disturbances is the main reason for the institutionalization of ad patients, as well as a major cause of the deterioration of the caregivers' sleep. the memento cohort is composed of patients with isolated memory complaints or mild cognitive impairment, at high risk to develop dementia. all voluntary patients from the cmrr (center of memory, resources and research) of bordeaux (memento cohort) will be tested at inclusion and followed-up 1 year later. for these two evaluations, actigraphic monitoring at home, 2-night polysomnography (psg) monitoring at hospital including a 24-hour period of urinary melatonin dosage, neuropsychological tests battery, a virtual reality tool and questionnaires will be used.


Eligibility criteria:
inclusion criteria for patients with mild cognitive impairment included in memento cohort: * aged 18 years and above * included in memento cohort within the last 3 months * clinical dementia rating scale ≤ 0,5 (not demented) * patients with mild cognitive impairment * visual and auditory acuity adequate for neuropsychological testing * having signed an informed consent * being affiliated to health insurance inclusion criteria for patients with mild cognitive impairment not included in memento cohort: * aged 18 years and above * first contact with memory clinic within the last 3 months * clinical dementia rating scale ≤ 0,5 (not demented) * patients with mild cognitive impairment * visual and auditory acuity adequate for neuropsychological testing * having signed an informed consent * being affiliated to health insurance inclusion criteria for healthy volunteers and control group: * aged 18 years and above * without evidence of psychopathology * volunteers matched in age, sex and educational level with patients * visual and auditory acuity adequate for neuropsychological testing * having signed an informed consent * being affiliated to health insurance exclusion criteria: * being under guardian conservator * residence in skilled nursing facility * pregnant or breast feeding woman * alzheimer's disease caused by gene mutations * having a neurological disease * history of stroke within the past three months * generalized anxiety (dsm-iv criteria) * schizophrenia history (dsm-iv criteria) * illiteracy, is unable to count or to read

Keywords: alzheimer sleep somnolence
resynchronization reverses remodeling in systolic left ventricular dysfunction (reverse)

Conditions: Heart Failure

Summary: heart failure is a progressive disease that decreases the pumping action of the heart. this may cause a backup of fluid in the heart and may result in heart beat changes. when there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. the purpose of the reverse clinical trial is to determine whether pacing in both the left and right ventricles using cardiac resynchronization therapy (crt) can help slow the progression of heart failure in people who have mild or previous symptoms and poor heart pumping function. this kind of therapy has previously been shown to reduce symptoms and improve exercise capacity in people with more advanced forms of heart failure.


Eligibility criteria:
inclusion criteria: * subjects with previously symptomatic heart failure but no current symptoms (new york heart association (nyha) class i, stage c) or subjects with mild heart failure that only sometimes interferes with daily activities (nyha class ii) * subjects with a qrs of 120 ms or more (the qrs interval is a measurement of how the electrical signal involved in a heart beat travels/conducts through the ventricles. a wide qrs (120 ms or more) suggests that there is a conduction problem (or block) in the ventricles). * subjects with a left ventricular ejection fraction less than or equal to 40%. (the left ventricular ejection fraction (lvef) is a measurement of how well the left ventricle pumps blood out to the rest of the body. the higher the lvef the more blood the ventricle is pumping.) * subjects with a left ventricular end diastolic dimension (lvedd) greater than or equal to 55. (the left ventricular end diastolic dimension (lvedd) is a measurement of heart size taken during an echocardiogram that is one indication of the health of the left ventricle.) exclusion criteria: * subjects who are pacemaker dependent (heart would not beat without the help of an implanted device to pace it). * subjects with heart failure that severely limits daily activities (nyha class iii) or subjects with severe heart failure with symptoms while resting (nyha class iv). * subjects hospitalized due to heart failure within past 3 months.

Keywords: heart failure implantable cardioverter defibrillator cardiac resynchronization therapy
genetic influence on statin pharmacodynamics

Conditions: Hyperlipidemia; Hypercholesterolemia; Dyslipidemia

Summary: the study intends to investigate whether genetics influence how individuals respond to statins (clinical outcomes and changes in carotid intimal media thickness)


Eligibility criteria:
inclusion criteria: * recently (within past 3 months) started taking atorvastatin, lovastatin, or simvastatin exclusion criteria: * concomitant uses of medications, supplements, or otcs known to interfere with statin metabolism
efficacy of topical 0.2% xanthan gum in patients with dry eye

Conditions: Dry Eye

Summary: the purpose of this study is to evaluate the effect of an ophthalmic solution containing 0.2% xanthan gum in reducing symptoms and signs of dry eye as well as tear film markers of oxidative stress.

oxidative stress is the result of an imbalance between the production of reactive oxygen species (ros) and antioxidant systems . the eye is constantly exposed to solar uv radiation which is the major inducer of ros production and therefore oxidative stress has been implicated in the pathogenesis of several eye disease, including dry eye. xanthan gum is a complex exopolysaccharide utilized as a food additive. its chemical structure shows a capacity to react with ros indicating a role as an anti-oxidative molecule. in the present study aging patients with dry eye will be enrolled. signs and symptoms of dry eye as well as levels of oxidative stress in tear will be evaluated afte 30 days of treatment with eye drops containing carboxymethylcellulose or xanthan gum.

Eligibility criteria:
inclusion criteria: * ocular surface disease index \> 12\ 59 yrs exclusion criteria: * contact lens wear and use of other ophthalmic solutions with the exception of artificial tears
identifying circadian rest-activity rhythm disorders in patients with advanced cancer

Conditions: Cancer; Circadian Rhythm Disorders; Sleep Disturbance; Activity, Motor; Accelerometry

Summary: circadian rest-activity rhythm disorders (cards) are common in patients with cancer, particularly in advanced disease. cards are associated with increased symptoms, poorer quality of life, poorer response to anticancer treatments and shorter survival. the goal of this observational study is to see how common cards are in patients with advanced cancer and to characterise their rest and activity patterns in more detail. a recent study has outlined a standard way to assess and diagnose a card. this study aims to assess patients with advanced cancer for a card using a novel screening tool against this newly formed diagnostic criteria. potentially modifiable risk factors will be considered along with associations between cards and symptoms, sleep preferences, sleep quality, daytime sleepiness, quality of life measures and predictors of survival.


Eligibility criteria:
inclusion criteria: * adult (18 years of age or older) * locally advanced or metastatic cancer * outpatient * ambulatory * prognosis of 3 months or more exclusion criteria: * inpatient * shiftworker * recent long-haul travel * cognitive impairment impacting on ability to complete questionnaires
washu diep flap video and patient understanding improvement

Conditions: Breast Cancer

Summary: patients will complete a survey before and after watching the washu diep flap video at their pre-operative standard of care visit, and a third survey at their post-operative standard of care visit. these surveys will use questions from sils, apais, pemat, and aim/iam to assess the patient's health literacy, demographics questions, and questions concerning patient understanding and anxiety surrounding the procedure. the purpose of the post-op survey will be to assess how well the video set expectations of the procedure and recovery process and will repeat questions asked pre-operatively. survey responses will be analyzed to determine if there are beneficial trends and improvement in patient understanding and anxiety due to adjunct video usage. primary objective: the primary aim of the study is to determine if our animated video affects understanding and anxiety survey scores in patients undergoing diep breast reconstruction.


Eligibility criteria:
inclusion criteria: * scheduled to have diep-flap breast reconstruction at barnes jewish hospital * speak english * ≥ 18 years of age exclusion criteria: * non-english speaking are excluded as the consent, questionnaires, and video are only available in english.

Keywords: pre-operative anxiety patient understanding breast reconstruction diep flap
a conversion study of immediate release (ir) and modified release (mr) forms of topiramate (tpm)

Conditions: Epilepsy

Summary: this multi-center, two-treatment study compares the pharmacokinetic profiles of immediate release (ir) and modified release (mr) formulations of topiramate (tpm) in patients with epilepsy.


Eligibility criteria:
inclusion criteria: 1. adult male or female patients with epilepsy on stable doses of topiramate. 2. able to voluntarily provide written informed consent to participate in the study. 3. use of an effective form of birth control if of child-bearing potential. exclusion criteria: 1. diagnosis of status epilepticus, non-epileptic seizures, or any progressive cns disease. 2. recent or recurrent suicidal thoughts or ideation. 3. clinically significant medical condition that may affect the safety of the subject. 4. females who are pregnant or lactating.
quantitative imaging and proton spectroscopy in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. results will be compared to age matched controls. investigators will assess lesions by measuring t2 and t1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (mtrhp) in patients with relapsing-remitting and secondary-progressive disease. this data will be correlated to total brain parenchymal volume as well as identifying the effect of ms lesions on the gray and white matter, volumetric disability, including kurtzke expanded disability status scale (edss) and a specific battery of neuropsychological tests. quantitative analysis of whole brain n-acetylaspartate (wbnaa), a reproducible measure of viable neuron number, using 1h mrs and compare the results to age-matched controls over duration of 5 years.


Eligibility criteria:
inclusion criteria: 1. patients with known ms diagnosis 2. age 7-110 years 3. males or females exclusion criteria: 1. medically unstable 2. artificial implants in the body 3. pregnant normal controls

Keywords: quantitative imaging of multiple sclerosis
gnrh for luteal support in ivf/icsi/fet cycles

Conditions: Infertility

Summary: during ivf cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. for a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. this process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. it has been found that after ivf additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in ivf cycle . recent data has shown that additional supplementation with a single administration of a gnrh agonist around the time the time of embryo transfer may further enhance these rates .

see above

Eligibility criteria:
inclusion criteria: * women undergoing ivf/icsi or frozen embryo transfers (fet) that less than 40 years old. exclusion criteria: * day 3 transfers
platelet rich plasma in levator ani muscle trauma

Conditions: Pelvic Floor Disorders

Summary: levator trauma (ballooning) often occurs after vaginal delivery. platelet rich plasma injection after delivery showed reduced hiatal area and maintain levator muscle strength.

this study aims to see if prp has a beneficial effect on the repair of pelvic floor muscle damage in primipara. therefore, this single-blinded randomized clinical trial compares the pelvic floor muscle repair in primipara following labor between the interventional group who received intramuscular prp injection in levator ani muscle and the control group, as assessed by ultrasonography, perineometry. the ultrasonography outcome measures include lower hiatal area during valsalva. the assessments are performed at multiple time points, which are before labor, 24-48 hours post-labor, 40 days post-labor, and 3 months post-labor.

Eligibility criteria:
inclusion criteria: * primigravida, in third trimester pregnancy * plan to do vaginal birth * have a clear address and telephone number that can be contacted * consent to participate in this study exclusion criteria: * history of pelvic floor disorder before pregnancy * history of pelvic surgery * avulsion of levator ani muscle (seen in usg) * unstable hemodynamic * trombocytopenia (\< 150,000) * anemia (hb\< 10) * sepsis * infection on perineum * corticosteroid intake within last 2 weeks * smoking * hematopoetic or bone cancer * delivery by c-section * no perineoraphy after birth

Keywords: platelet rich plasma levator ani muscle post-partum trauma ballooning trauma levator ani muscle strength
supervised exercise-training in children with insulin resistance or healthy metabolic profile

Conditions: Metabolism Disorder; Insulin Sensitivity; Obesity, Pediatric

Summary: despite exercise training decrease blood fasting glycemia in 'average' terms, there is a wide interindividual variability after exercise training explored mainly in adults but not in children. thus, is yet unknown what baseline health status as well as the influence of what health variable may produce more/less non-responder (nr) prevalence (i.e., percentage of subjects who experienced a non-change/worsened response after training in some metabolic outcomes) after exercise training in school children.


Eligibility criteria:
inclusion criteria: * diagnosed of insulin resistance by one of three plasmatic glucose control: homa-ir ≥3.0, * fasting insulin levels ≥15 µui/dl or fasting glucose ≥100 and ≤126 mg/dl within the enrolment stage applied at school (i.e., ≤3 months), * physical inactivity (volume of ≤60 min/day of moderate physical activity), * to be participating of regular practical physical education classes at school (i.e., 90 min/week), * living only in urban areas. exclusion criteria: * potential medical, musculoskeletal problems or a familial history of t2dm, * ischemic disease, * arrhythmia, * asthma, * utilization of drugs that modulate the metabolic and respiratory control.
immediate effects of alliance therapy in modulation of pain and disability in subjects with knee osteoarthritis

Conditions: Arthritis; Knee Osteoarthritis

Summary: introduction: the osteoarthritis (oa) is the most common type of joint disease, its features include joint space narrowing, osteophytes formation of the joint margins, motor deficit, reduced strength, and persistent pain. as a treatment option physiotherapy has several resources for the patient approach. however, the effect of treatment is not only the application of therapeutic techniques and resources but also to existing contextual factors such as the therapeutic alliance. objective: to assess the effects of an intervention with the focus on positive therapeutic alliance in subjects oa knee on pain and disability. methods: this is a randomized study of two arms with a blind evaluator. 40 subjects were randomized into 2 groups: group 1 "kinesio taping® kt" group 2 " kinesio taping® with therapeutic alliance kt+at". both groups received the application of kinesio taping® method as the concepts of the original method. the group "kt+at" session was conducted in order to increase the relationship between the therapist and the patient.


Eligibility criteria:
inclusion criteria: * patients with both sexes from 40 to 80 years old * who underwent imaging examination evidencing grade ii or iii knee osteoarthritis according to the kellgren and lawrence classification * who were referred to the physiotherapy service by a physician. exclusion criteria: * patients who are unable to walk * with a history of cancer * associated neurological diseases * morbid obesity
study of the long term outcome of tuberculous meningitis in vietnamese adults treated with adjunctive dexamethasone

Conditions: Tuberculosis Meningitis

Summary: all patients who were alive at the end of the dexamethasone treatment trial conducted by oxford university clinical research unit from 2001-2005 (n=340) will be eligible to participate in this long-term follow-up study. all eligible and consenting patients will undergo an assesment consisting of a simple questionnaire, a clinical examination and a blood test. data collected will focus on survival, neurological disability and tuberculosis relapse. data will be collected in individual case record forms and entered into a computer database.


Eligibility criteria:
inclusion criteria:patients were alive at the end of the dexamethasone study (n=340) will be eligible to participate in this long-term follow-up study informed consent exclusion criteria: patients without informed consent

Keywords: tuberculosis meningitis
acupuncture in the treatment of fatigue in parkinson's disease

Conditions: Parkinson Disease; Fatigue

Summary: this study evaluates the efficacy of acupuncture in the treatment of fatigue in participants with parkinson's disease. half of participants will receive real acupuncture while the half will receive placebo acupuncture.

this will be a single centre, single blinded 2-group randomized controlled study, with participants receiving either verum acupuncture or placebo acupuncture. a retractable non-invasive placebo needle will be used in the placebo arm. both the real and placebo needles have a fine needle body and copy handle and look exactly the same. however, the placebo needle has a retractable shaft and blunt tip. when pressed onto the skin, it telescopes into the handle and the blunt tip stays on the skin instead of penetrating it. the plastic tube with adhesive foot-plate is placed on the skin to hold it in place. the real needle, on the other hand, has a normal sharp tip which allows it to pierce the skin. the following acupoints will be needled: stomach 36 (bilateral), spleen 6 (bilateral), kidney 3 (bilateral), large intestine 4 (bilateral), pericardium 6 (bilateral), and conception vessel 6. these points were chosen based on traditional chinese medicine theory (which attributed fatigue to deficiencies of spleen, kidney and qi). each acupuncture session will be based on a strict protocol, and conversation between acupuncturists and participants will be kept to a minimum. participants will be assessed at 3 intervals: 1. week 0 (baseline) 2. week 5 (completion of intervention) 3. week 9 (4 weeks after completion of intervention

Eligibility criteria:
inclusion criteria: 1. diagnosis of pd based on criteria developed by gelb et al which is adopted by the national institute of neurological disorders and stroke, us national institute of health. 2. age 21-85 years old 3. presence of persistent fatigue of a moderate level for at least 4 weeks' duration. moderate fatigue is defined as a score of ≥10 on the general fatigue domain of the multidimensional fatigue inventory. 4. no acupuncture treatment in the past 6 months. exclusion criteria: 1. significant cognitive, language or psychiatric illnesses which prevents the subject from understanding instructions and participating in the study. 2. needle phobia 3. comorbidity with a bleeding disorder 4. known anemia with hemoglobin level less than 10g/dl. 5. known congestive cardiac failure and/or end stage renal disease 6. female subjects of childbearing age 7. presence of symptomatic postural hypotension
the safety and efficacy of risperidone as adjunctive therapy to mood stabilizers in the long-term treatment of bipolar mania

Conditions: Bipolar Disorder

Summary: the purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania

the use of mood stabilizers such as lithium and carbamazepine is known to be effective for preventing and treating bipolar disorder. but the use of antipsychotic drugs is more effective in patients suffering severe episodes of mania as it elicits behavioral changes and spurs the effects of mood stabilizers. antipsychotic drugs are used for patients who failed to respond to mood stabilizers or for the acute management of manic episodes associated with bipolar disorders. this study aims to evaluate the safety and efficacy of risperidone as an adjunctive therapy to mood stabilizers in the long-term treatment (6months) of bipolar disorder using various assessment instruments, including the young mania rating scale. the simpson-angus rating scale will be also employed to assess the presence of extrapyramidal side effects and other adverse events. the patients will receive orally 0.5, 1, 2 mg risperidone tablet once daily for 6 months

Eligibility criteria:
inclusion criteria: * in- or out-patient * diagnosis of bipolar i disorder * most recent episode manic with or without psychotic features * ymrs \> 20 (manic) * need antipsychotic combination on the basis of clinicians' experience exclusion criteria: * rapid cycling * risk of suicide or violence * history of substance dependence within 3 months * comorbidities * unstable medical illness * previous sensitivity history to risperidone * pregnant woman or those without proper contraception * history of clozapine and one cycle of depot use prior to entry * history of treatment resistance: at least two mood stabilizers * prior history of active treatment with risperidone * as for patients having wash-out period, patients that show 25% or more decrease in ymrs at baseline as compared to that at enrollment time, should be excluded.

Keywords: bipolar risperidone adjunctive therapy